These hormones help regulate blood sugar levels and appetite, making them valuable tools for those struggling with obesity and type 2 diabetes
Private insights, not public feeds Everything you log stays private unless you choose to share it
Combining the therapeutic approaches of GLP-1 agonists (which target extrahepatic mechanisms for metabolic disorders) with resmetirom (which target intrahepatic mechanisms for MASH and liver fibrosis) seems like a promising strategy for addressing fat accumulation, inflammation, and fibrosis associated with MASH
Risks of Switching From Semaglutide to Tirzepatide Adverse Effects : Both medications may have commonly reported side effects which are generally gastrointestinal disturbances (nausea, vomiting, diarrhea, stomach upset) and injection-site reactions (1,2,4,5)
Not sure whether your Retatrutide results are being affected by timing, recovery, or something else
Data related to Orforglipron's Phase 3 ACHIEVE-1 program results (HbAc reduction, weight loss, dosing flexibility, side effects) and upcoming Phase 4 studies
